FY2029 Earnings Estimate for CRBP Issued By B. Riley

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Equities research analysts at B. Riley issued their FY2029 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a report released on Wednesday, November 26th. B. Riley analyst M. Mamtani forecasts that the biopharmaceutical company will earn ($4.82) per share for the year. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.80) by ($0.10).

A number of other research analysts have also recently commented on CRBP. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Corbus Pharmaceuticals in a research report on Monday, October 20th. Royal Bank Of Canada cut their price objective on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an “outperform” rating for the company in a research note on Thursday, November 13th. Wedbush lifted their target price on shares of Corbus Pharmaceuticals from $31.00 to $38.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. Mizuho set a $39.00 price target on shares of Corbus Pharmaceuticals in a research report on Wednesday, October 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.38.

Corbus Pharmaceuticals Trading Down 3.2%

Shares of NASDAQ CRBP opened at $11.50 on Thursday. The stock’s 50-day moving average is $13.65 and its 200 day moving average is $10.45. The stock has a market cap of $201.77 million, a price-to-earnings ratio of -2.41 and a beta of 2.69. Corbus Pharmaceuticals has a 1-year low of $4.64 and a 1-year high of $20.56.

Insiders Place Their Bets

In other Corbus Pharmaceuticals news, CEO Yuval Cohen sold 8,973 shares of the business’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $17.14, for a total value of $153,797.22. Following the transaction, the chief executive officer owned 138,187 shares in the company, valued at approximately $2,368,525.18. The trade was a 6.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sean F. Moran sold 12,981 shares of the company’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $17.02, for a total transaction of $220,936.62. Following the transaction, the chief financial officer directly owned 73,313 shares of the company’s stock, valued at approximately $1,247,787.26. This trade represents a 15.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 41,674 shares of company stock worth $713,870. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Corton Capital Inc. bought a new stake in shares of Corbus Pharmaceuticals in the 2nd quarter worth approximately $86,000. ADAR1 Capital Management LLC purchased a new stake in Corbus Pharmaceuticals in the third quarter worth $129,000. Marshall Wace LLP bought a new stake in Corbus Pharmaceuticals in the second quarter valued at $137,000. Baker Avenue Asset Management LP bought a new stake in Corbus Pharmaceuticals in the second quarter valued at $138,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Corbus Pharmaceuticals during the 2nd quarter valued at $141,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.